经典名方研发建议的梳理和探讨
|
摘要
经典名方是中医方剂的杰出代表,临床治病的有效工具,中医药传统文化的精髓。经典名方的研发引起中医药整个产业链群体的高度关注和重视,一系列指导性建议和针对性文献为经典名方的研发奠定了良好基础。该文基于CNKI数据库,对经典名方研发建议或启示的文献进行整理、提炼,分析各家之说、汲取各家之议,博采众长,构建经典名方研发轮廓,得出文献研究是前提、优质药材/饮片是基础、物质基准是核心、高品质是保障和优惠政策是动力的启示,并展开相关探讨,为促进经典名方研发及相关产业发展提供参考。
Classical traditional Chinese medicine(TCM) excellent prescriptions is an outstanding representative in prescriptions of traditional Chinese medicine,clinical medicine effective tool,and the essence of traditional culture of Chinese medicine.The research and development of classical TCM excellent prescriptions has attracted great attention from group in the whole industry chain of TCM,a series of guiding suggestions and targeted literature laid a good foundation for research and development of classical TCM excellent prescriptions.In this paper,based on the CNKI database,literature about suggestions or enlightenments of classical TCM excellent prescriptions was sorted and refined in order to build the research outline of classical TCM excellent prescriptions,and it was concluded that literature research was the premise,medicine/decoction pieces with good quality was the foundation,standard substance was the core,high quality was the guarantee and preferential policies were the impetus,and related discussions were carried out.All these were expected to promote the research of classical TCM excellent prescriptions and development of related industries.
Classical traditional Chinese medicine(TCM) excellent prescriptions is an outstanding representative in prescriptions of traditional Chinese medicine,clinical medicine effective tool,and the essence of traditional culture of Chinese medicine.The research and development of classical TCM excellent prescriptions has attracted great attention from group in the whole industry chain of TCM,a series of guiding suggestions and targeted literature laid a good foundation for research and development of classical TCM excellent prescriptions.In this paper,based on the CNKI database,literature about suggestions or enlightenments of classical TCM excellent prescriptions was sorted and refined in order to build the research outline of classical TCM excellent prescriptions,and it was concluded that literature research was the premise,medicine/decoction pieces with good quality was the foundation,standard substance was the core,high quality was the guarantee and preferential policies were the impetus,and related discussions were carried out.All these were expected to promote the research of classical TCM excellent prescriptions and development of related industries.
引文
[1]国家食品药品监督管理总局.关于印发中药注册管理补充规定的通知[EB/OL].http://samr.cfda.gov.cn/WS01/CL0844/27432.html,2018-01-07/2018-09-17.
[2]全国人民代表大会.中华人民共和国中医药法[EB/OL].http://www.npc.gov.cn/npc/xinwen/syxw/2016-12/25/content_2006116.htm,2016-12-25/2018-09-17.
[3]国家中医药管理局.关于发布《古代经典名方目录(第一批)》的通知[EB/OL].http://kjs.satcm.gov.cn/zhengcewenjian/2018-04-16/7107.html,2018-04-13/2018-09-18.
[4]国家药品监督管理局.关于发布古代经典名方中药复方制剂简化注册审批管理的规定的公告[EB/OL].http://cnda.cfda.gov.cn/WS04/CL2050/228247.html,2018-05-29/2018-06-01.
[5]杨明,伍振峰,郑琴,等.中药经典名方开发与制剂研究的关键问题[J].中草药,2010,41(10):1590-1592.
[6]高旭军,龙杰.我国中医药经典名方保护之探究[J].中国版权,2013(3),54-58.
[7]薛斐然,周贝.日本汉方制剂对我国经典名方注册监管的启示[J].世界科学技术-中医药现代化,2017,19(4):587-589.
[8]王智民,刘菊研,刘晓谦,等.谈经典名方的化学、生产和质量控制研发和监管[J].中国中药杂志,2017,42(10):1819-1824.
[9]陈畅,程锦堂,刘安.经典名方研发策略[J].中国中药杂志,2017,42(9):1814-1818.
[10]薛斐然,刘炳林,周贝.日本汉方制剂说明书与我国中成药说明书对比浅析[J].中国现代中药,2017,19(6):877-879.
[11]徐旭,王玉丽,涂正伟,等.经典名方药理学研究思路探讨[J].药物评价研究,2017,40(12):1816-1827.
[12]陈雪梅,蔡秋杰,张华敏,等.日本汉方药概况及其对我国中医古代经典名方制剂研发的启示[J].中国中医药图书情报杂志,2018,42(2):1-4.
[13]杨平,林丹,宋菊,等.日本汉方制剂及其特点与中药新药研究的思考[J].中草药,2018,49(9):1985-1989.
[14]梁爱华,韩佳寅,陈士林,等.中药经典名方的质量和安全性考量[J].中国食品药品监管,2018(6):1-10.
[15]丁腾,李耿,张红,等.日本汉方药产业发展现状分析及思考[J].中国现代中药,2018,20(7):785-790.
[16]杨洪军,黄璐琦.经典名方的研发---中医药传承发展的突破口之一[J].中国现代中药,2018,20(7):775-779.
[17]兰青山,肖苏萍,黄掌欣,等.谈经典名方现阶段政策法规之启示[J].中国现代中药,2018,20(7):780-784.
[18]刘冠萍.经典名方创新开发初步探讨与研究[J].企业科技与发展,2018(7):68-69.
[19]熊兴江,王阶.经典名方治疗高血压病临床实践[J].中国中药杂志,2014,39(5):929-933.
[20]张定棋,徐莹,慕永平,等.下瘀血汤抗肝纤维化作用及其机制研究进展[J].中国实验方剂学杂志,2018,24(21):219-224.
[21]董燕,侯酉娟,李莎莎,等.经典名方羌活胜湿汤的古代文献分析[J].中国实验方剂学杂志,2018,24(17):1-5.
[22]李晓霞,徐旭,马会霞,等.经典名方桂枝茯苓丸的临床和实验研究进展[J].药物评价研究,2018,41(9):1724-1729.
[23]王嘉伦,卫军营,范建伟,等.基于古代文献分析经典名方四逆汤的主治疾病[J].中国实验方剂学杂志,2018,24(18):1-4.
[24]张卫,黄璐琦,李超霞,等.金银花品种的本草考证[J].中国中药杂志,2014,39(12):2239-2245.
[25]高晓娟,赵丹,赵建军,等.甘草的本草考证[J].中国实验方剂学杂志,2017,23(2):193-198.
[26]赵容,许亮,谢明,等.中药玉竹的本草考证[J].中国实验方剂学杂志,2017,23(15):227-234.
[27]修彦凤,张永太,王兴发,等.半夏的炮制历史沿革[J].时珍国医国药,2006,17(9):1774-1775.
[28]黄英杰.《伤寒论》用药剂量及其相关问题的研究[D].北京:北京中医药大学,2007.
[29]李明,周强,杨丽娜,等.基于历代中医方剂文献探索石膏在汤剂中的常用剂量[J].中国实验方剂学杂志,2018,24(8):29-33.
[30]孟菲,杨丰滇,巩洋阳,等.中医药古籍中药饮片处方剂量研究[J].中医研究,2018,31(9):61-63.
[31]钟文,陈莎,章军,等.重点是原料,还是工艺?---以葛根芩连汤为例探讨中成药质量一致性控制方法[J].中国中药杂志,2016,41(6):1027-1032.
[32]张萍,李明华,石岩,等.2013-2016年我国中药材及饮片质量状况及相关问题探讨[J].中国药事,2018,32(4):438-443.
[33]欧阳楠,琚健.从中药制剂生产用中药材及中药饮片质量问题谈监管模式[J].中国药学杂志,2018,53(3):239-243.
[34]杨光,郭兰萍,周修腾,等.中药材规范化种植(GAP)几个关键问题商榷[J].中国中药杂志,2016,41(7):1173-1177.
[35]李耿,程煜华,郭宇博,等.中药大品种科技竞争力报告(2017版)[J].中国现代中药,2018,20(1):6-13.
[2]全国人民代表大会.中华人民共和国中医药法[EB/OL].http://www.npc.gov.cn/npc/xinwen/syxw/2016-12/25/content_2006116.htm,2016-12-25/2018-09-17.
[3]国家中医药管理局.关于发布《古代经典名方目录(第一批)》的通知[EB/OL].http://kjs.satcm.gov.cn/zhengcewenjian/2018-04-16/7107.html,2018-04-13/2018-09-18.
[4]国家药品监督管理局.关于发布古代经典名方中药复方制剂简化注册审批管理的规定的公告[EB/OL].http://cnda.cfda.gov.cn/WS04/CL2050/228247.html,2018-05-29/2018-06-01.
[5]杨明,伍振峰,郑琴,等.中药经典名方开发与制剂研究的关键问题[J].中草药,2010,41(10):1590-1592.
[6]高旭军,龙杰.我国中医药经典名方保护之探究[J].中国版权,2013(3),54-58.
[7]薛斐然,周贝.日本汉方制剂对我国经典名方注册监管的启示[J].世界科学技术-中医药现代化,2017,19(4):587-589.
[8]王智民,刘菊研,刘晓谦,等.谈经典名方的化学、生产和质量控制研发和监管[J].中国中药杂志,2017,42(10):1819-1824.
[9]陈畅,程锦堂,刘安.经典名方研发策略[J].中国中药杂志,2017,42(9):1814-1818.
[10]薛斐然,刘炳林,周贝.日本汉方制剂说明书与我国中成药说明书对比浅析[J].中国现代中药,2017,19(6):877-879.
[11]徐旭,王玉丽,涂正伟,等.经典名方药理学研究思路探讨[J].药物评价研究,2017,40(12):1816-1827.
[12]陈雪梅,蔡秋杰,张华敏,等.日本汉方药概况及其对我国中医古代经典名方制剂研发的启示[J].中国中医药图书情报杂志,2018,42(2):1-4.
[13]杨平,林丹,宋菊,等.日本汉方制剂及其特点与中药新药研究的思考[J].中草药,2018,49(9):1985-1989.
[14]梁爱华,韩佳寅,陈士林,等.中药经典名方的质量和安全性考量[J].中国食品药品监管,2018(6):1-10.
[15]丁腾,李耿,张红,等.日本汉方药产业发展现状分析及思考[J].中国现代中药,2018,20(7):785-790.
[16]杨洪军,黄璐琦.经典名方的研发---中医药传承发展的突破口之一[J].中国现代中药,2018,20(7):775-779.
[17]兰青山,肖苏萍,黄掌欣,等.谈经典名方现阶段政策法规之启示[J].中国现代中药,2018,20(7):780-784.
[18]刘冠萍.经典名方创新开发初步探讨与研究[J].企业科技与发展,2018(7):68-69.
[19]熊兴江,王阶.经典名方治疗高血压病临床实践[J].中国中药杂志,2014,39(5):929-933.
[20]张定棋,徐莹,慕永平,等.下瘀血汤抗肝纤维化作用及其机制研究进展[J].中国实验方剂学杂志,2018,24(21):219-224.
[21]董燕,侯酉娟,李莎莎,等.经典名方羌活胜湿汤的古代文献分析[J].中国实验方剂学杂志,2018,24(17):1-5.
[22]李晓霞,徐旭,马会霞,等.经典名方桂枝茯苓丸的临床和实验研究进展[J].药物评价研究,2018,41(9):1724-1729.
[23]王嘉伦,卫军营,范建伟,等.基于古代文献分析经典名方四逆汤的主治疾病[J].中国实验方剂学杂志,2018,24(18):1-4.
[24]张卫,黄璐琦,李超霞,等.金银花品种的本草考证[J].中国中药杂志,2014,39(12):2239-2245.
[25]高晓娟,赵丹,赵建军,等.甘草的本草考证[J].中国实验方剂学杂志,2017,23(2):193-198.
[26]赵容,许亮,谢明,等.中药玉竹的本草考证[J].中国实验方剂学杂志,2017,23(15):227-234.
[27]修彦凤,张永太,王兴发,等.半夏的炮制历史沿革[J].时珍国医国药,2006,17(9):1774-1775.
[28]黄英杰.《伤寒论》用药剂量及其相关问题的研究[D].北京:北京中医药大学,2007.
[29]李明,周强,杨丽娜,等.基于历代中医方剂文献探索石膏在汤剂中的常用剂量[J].中国实验方剂学杂志,2018,24(8):29-33.
[30]孟菲,杨丰滇,巩洋阳,等.中医药古籍中药饮片处方剂量研究[J].中医研究,2018,31(9):61-63.
[31]钟文,陈莎,章军,等.重点是原料,还是工艺?---以葛根芩连汤为例探讨中成药质量一致性控制方法[J].中国中药杂志,2016,41(6):1027-1032.
[32]张萍,李明华,石岩,等.2013-2016年我国中药材及饮片质量状况及相关问题探讨[J].中国药事,2018,32(4):438-443.
[33]欧阳楠,琚健.从中药制剂生产用中药材及中药饮片质量问题谈监管模式[J].中国药学杂志,2018,53(3):239-243.
[34]杨光,郭兰萍,周修腾,等.中药材规范化种植(GAP)几个关键问题商榷[J].中国中药杂志,2016,41(7):1173-1177.
[35]李耿,程煜华,郭宇博,等.中药大品种科技竞争力报告(2017版)[J].中国现代中药,2018,20(1):6-13.